Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

Although treatment-resistant schizophrenia (TRS) was described 50 years ago 1 and has a
gold standard treatment with clozapine based on well-defined criteria, 2 there is still a matter …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Aims Guidance on clozapine dosing in treatment‐resistant schizophrenia is based largely
on data from White young adult males. This study aimed to investigate the pharmacokinetic …

Objective Clozapine is substantially underutilized in most countries and clinician factors
including lack of knowledge and concerns about adverse drug effects (ADEs) contribute …

Purpose Although clozapine was Food and Drug Administration (FDA) approved more than
3 decades ago, major barriers and gaps in knowledge continue to prevent its effective and …

Objective To clarify the effects of smoking on the disposition of two commonly used
antipsychotics, olanzapine and clozapine, and to create standards to adjust the doses of …

Seizures are a known adverse effect of clozapine therapy. The literature varies on incidence
rates of seizures, secondary to varying time frames in which each seizure occurred. Tonic …